CBS
She's given goggles that impair sight... headphones that give off distracting noises... a pair of gloves with popcorn kernels in the finger tips to simulate arthritis... then more kernels are placed in her shoes. To finish it off, sister stella tapes some of her fingers together for limited dexterity.
Amy Kennedy is now ready to take the virtual dementia tour...an experience designed to give perfectly healthy individuals a chance to see what day to day life would be like if they suffered from alzheimer's or dementia. She admits, "You can do all that dementia training, i've had every dementia training there is, but making yourself go through it is a lot different than hearing it in a classroom."
But the tour is much more than just a crazy outfit. Once you're garbed up, you're taken into the testing room, which is designed to look like a residence room. Then, you're given 5 simple, everyday tasks to do... sounds easy, right? Turn's out, it.....read the whole story
For more dementia information, click here
For Alzheimer's and dementia activities, click here
For information on being the best caregiver you can be, click here
For a great resource for those with dementia, caregivers and healthcare professinals, click here
Susan Berg, dementia expert, shares practical help for caregivers of those with dementia including easy to do activities
Friday, March 6, 2009
Wednesday, March 4, 2009
Study suggests how Alzheimer's attacks brain
Stuff.conz
US scientists proposed a new theory of how Alzheimer's disease kills brain cells they said opens new avenues of research into treatments for the fatal, brain-wasting disease.
They believe a chemical mechanism that naturally prunes away unwanted brain cells during early brain development somehow gets hijacked in Alzheimer's disease.
"The key player we're focusing on is a protein called APP," said Marc Tessier-Lavigne, executive vice president of research drug discovery at the US biotechnology company Genentech Inc , whose study appears in the journal Nature.
Tessier-Lavigne said amyloid precursor protein, or APP -- a key building block in brain plaques found in Alzheimer's disease -- is the driving force behind this process.
"We know that APP is...read the whole article
For more dementia information, click here
For Alzheimer's and dementia activities, click here
For information on being the best caregiver you can be, click here
For a great resource for those with dementia, caregivers and healthcare professinals, click here
US scientists proposed a new theory of how Alzheimer's disease kills brain cells they said opens new avenues of research into treatments for the fatal, brain-wasting disease.
They believe a chemical mechanism that naturally prunes away unwanted brain cells during early brain development somehow gets hijacked in Alzheimer's disease.
"The key player we're focusing on is a protein called APP," said Marc Tessier-Lavigne, executive vice president of research drug discovery at the US biotechnology company Genentech Inc , whose study appears in the journal Nature.
Tessier-Lavigne said amyloid precursor protein, or APP -- a key building block in brain plaques found in Alzheimer's disease -- is the driving force behind this process.
"We know that APP is...read the whole article
For more dementia information, click here
For Alzheimer's and dementia activities, click here
For information on being the best caregiver you can be, click here
For a great resource for those with dementia, caregivers and healthcare professinals, click here
Friday, February 27, 2009
Rate of memory decline differs by dementia type
Reuters UK
By Scott Baltic
NEW YORK (Reuters Health) - The rate at which people with dementia lose their memory differs significantly according to the type of dementia they have, new research from France suggests. The research also highlights the importance of early health care in elderly people who develop dementia.
After Alzheimer's disease (AD) alone, AD with cerebrovascular disease and vascular dementia are the leading causes of dementia. Vascular dementia is often associated with stroke. High blood pressure and smoking are risk factors.
Little is known about the progression of either AD with cerebrovascular disease or vascular dementia, Dr. Florence Pasquier of Hopital Salengro in Lille and colleagues note.
To investigate, they followed......read the whole story
For more dementia information, click here
For Alzheimer's and dementia activities, click here
For information on being the best caregiver you can be, click here
For a great resource for those with dementia, caregivers and healthcare professinals, click here
By Scott Baltic
NEW YORK (Reuters Health) - The rate at which people with dementia lose their memory differs significantly according to the type of dementia they have, new research from France suggests. The research also highlights the importance of early health care in elderly people who develop dementia.
After Alzheimer's disease (AD) alone, AD with cerebrovascular disease and vascular dementia are the leading causes of dementia. Vascular dementia is often associated with stroke. High blood pressure and smoking are risk factors.
Little is known about the progression of either AD with cerebrovascular disease or vascular dementia, Dr. Florence Pasquier of Hopital Salengro in Lille and colleagues note.
To investigate, they followed......read the whole story
For more dementia information, click here
For Alzheimer's and dementia activities, click here
For information on being the best caregiver you can be, click here
For a great resource for those with dementia, caregivers and healthcare professinals, click here
Thursday, February 26, 2009
Mechanisms That Prevent Alzheimer's Disease: Enzymatic Activity Plays Key Role
ScienceDaily— In a project involving the collaboration of several institutes, research scientists of the Johannes Gutenberg University Mainz have succeeded in gaining further insight in the functioning of endogenous mechanisms that protect against the development of Alzheimer's disease. It was found that the activity of the enzyme α-secretase is mainly responsible for the protective effect.
"In the past, we postulated that the enzyme α-secretase was involved in preventing the formation of cerebral plaques characteristic of Alzheimer's disease and also enhanced cerebral functions, such as learning and memory," explained Professor Falk Fahrenholz of the Institute of Biochemistry. His research group has been working in cooperation with the Clinic of Psychiatry and Psychotherapy of the university's Faculty of Medicine and the Central Animal Laboratory Facility (ZVTE) to discover the mechanism for the beneficial effects of α-secretase. The Journal of Alzheimer's Disease (JAD) presents the results of this project in its February 2009 issue.
α-secretase is an endogenous enzyme that is present in the nerve cells of the brain, where it is responsible for the cleavage of an Aβ into Aβ domain. The result is a soluble protein fragment that promotes the growth of nerve cells and thus prevents the development of cerebral deterioration caused by Aβ. However, if the enzyme β-secretase is active, a chain reaction is initiated that subsequently results in the development....read the whole article
For more dementia information, click here
For Alzheimer's and dementia activities, click here
For information on being the best caregiver you can be, click here
For a great resource for those with dementia, caregivers and healthcare professinals, click here
"In the past, we postulated that the enzyme α-secretase was involved in preventing the formation of cerebral plaques characteristic of Alzheimer's disease and also enhanced cerebral functions, such as learning and memory," explained Professor Falk Fahrenholz of the Institute of Biochemistry. His research group has been working in cooperation with the Clinic of Psychiatry and Psychotherapy of the university's Faculty of Medicine and the Central Animal Laboratory Facility (ZVTE) to discover the mechanism for the beneficial effects of α-secretase. The Journal of Alzheimer's Disease (JAD) presents the results of this project in its February 2009 issue.
α-secretase is an endogenous enzyme that is present in the nerve cells of the brain, where it is responsible for the cleavage of an Aβ into Aβ domain. The result is a soluble protein fragment that promotes the growth of nerve cells and thus prevents the development of cerebral deterioration caused by Aβ. However, if the enzyme β-secretase is active, a chain reaction is initiated that subsequently results in the development....read the whole article
For more dementia information, click here
For Alzheimer's and dementia activities, click here
For information on being the best caregiver you can be, click here
For a great resource for those with dementia, caregivers and healthcare professinals, click here
Wednesday, February 25, 2009
Boston Docs Study Promising New Alzheimer's Drug
BOSTON (WBZ) ―
Alzheimer's May Affect Patients' Memory Earlier (2/19/2009)
Massachusetts researchers are looking for patients to test a promising new Alzheimer's drug. Experts believe it could be the first drug to actually slow down the disease.
Irene Courchesne was diagnosed with early symptoms of Alzheimer's three years ago. "Things started to get really funny," Irene said. "I couldn't remember. I used to have to go to court and I couldn't get my stuff correct."
That's why Irene decided to take part in a new clinical trial being done at the Boston University School of Medicine.
Researchers at B.U. are testing a promising new drug which they believe can actually slow down the progression of Alzheimer's, instead of just temporarily treating the symptoms like current treatments.
Dr. Robert Stern, co-director of the Alzheimer's disease Clinical and Research Program at the B.U. School of Medicine explains, "This new drug has as its goal the ability to suck out the amyloid proteins from the brain which we think is the cause of Alzheimer's and will dramatically alter the course of Alzheimer's disease."
Irene Courchesne, who enrolled in the study in December, says she started to notice....read the whole article
For more dementia information, click here
For Alzheimer's and dementia activities, click here
For information on being the best caregiver you can be, click here
For a great resource for those with dementia, caregivers and healthcare professinals, click here
Alzheimer's May Affect Patients' Memory Earlier (2/19/2009)
Massachusetts researchers are looking for patients to test a promising new Alzheimer's drug. Experts believe it could be the first drug to actually slow down the disease.
Irene Courchesne was diagnosed with early symptoms of Alzheimer's three years ago. "Things started to get really funny," Irene said. "I couldn't remember. I used to have to go to court and I couldn't get my stuff correct."
That's why Irene decided to take part in a new clinical trial being done at the Boston University School of Medicine.
Researchers at B.U. are testing a promising new drug which they believe can actually slow down the progression of Alzheimer's, instead of just temporarily treating the symptoms like current treatments.
Dr. Robert Stern, co-director of the Alzheimer's disease Clinical and Research Program at the B.U. School of Medicine explains, "This new drug has as its goal the ability to suck out the amyloid proteins from the brain which we think is the cause of Alzheimer's and will dramatically alter the course of Alzheimer's disease."
Irene Courchesne, who enrolled in the study in December, says she started to notice....read the whole article
For more dementia information, click here
For Alzheimer's and dementia activities, click here
For information on being the best caregiver you can be, click here
For a great resource for those with dementia, caregivers and healthcare professinals, click here
Sunday, February 22, 2009
Small Vessel Injury from Hypertension or Diabetes May Lead to Dementia
SeniorJournal.com
One-third of risk for dementia attributed to small vessel disease in autopsy study
A large autopsy study of senior citizens who had lived in the Seattle area has found that as many as one-third of those who had dementia before they died also had small vessel damage in their brains – the type of cumulative injury that can result from hypertension or diabetes. The researchers say it suggests this accounts for a third of the risk for dementia.
In the autopsied brains of people who had experienced cognitive decline and dementia, 45 percent of the risk for dementia was associated with pathologic changes of Alzheimer's disease.
Another 10 percent of dementia risk was associated with.....read the whole article
For more dementia information, click here
For Alzheimer's and dementia activities, click here
For information on being the best caregiver you can be, click here
For a great resource for those with dementia, caregivers and healthcare professinals, click here
One-third of risk for dementia attributed to small vessel disease in autopsy study
A large autopsy study of senior citizens who had lived in the Seattle area has found that as many as one-third of those who had dementia before they died also had small vessel damage in their brains – the type of cumulative injury that can result from hypertension or diabetes. The researchers say it suggests this accounts for a third of the risk for dementia.
In the autopsied brains of people who had experienced cognitive decline and dementia, 45 percent of the risk for dementia was associated with pathologic changes of Alzheimer's disease.
Another 10 percent of dementia risk was associated with.....read the whole article
For more dementia information, click here
For Alzheimer's and dementia activities, click here
For information on being the best caregiver you can be, click here
For a great resource for those with dementia, caregivers and healthcare professinals, click here
Friday, February 20, 2009
Gender-wise absorbent briefs differ in more ways than 1
If your loved one with dementia is incontinent, you may be interested in this
Kimberly-Clark to introduce new product for $1.2 billion market
By Bill Glauber of the Journal Sentinel
Neenah - On a conference room table inside the sprawling campus of Kimberly-Clark Corp., Greg Fries lays out the past, present and future of adult absorbent underwear.
There's a 1980s version of the Depend brand of incontinence products, an all-white, padded item that looks to the untrained eye like a giant diaper. There's a 1990s version, what amounts to unisex underwear, no-nonsense and no-frills.
And, coming to store shelves by early spring, there is what the company calls "its first line of gender-specific adult absorbent underwear."
That would be Depend protective underwear for men and women. There's a pink waistband for women and a blue one for men. Moreover, the leg opening for men is narrower than it is for women.
"One of the key insights we got was.......read the whole story
For more dementia information, click here
For Alzheimer's and dementia activities, click here
For information on being the best caregiver you can be, click here
For a great resource for those with dementia, caregivers and healthcare professinals, click here
Kimberly-Clark to introduce new product for $1.2 billion market
By Bill Glauber of the Journal Sentinel
Neenah - On a conference room table inside the sprawling campus of Kimberly-Clark Corp., Greg Fries lays out the past, present and future of adult absorbent underwear.
There's a 1980s version of the Depend brand of incontinence products, an all-white, padded item that looks to the untrained eye like a giant diaper. There's a 1990s version, what amounts to unisex underwear, no-nonsense and no-frills.
And, coming to store shelves by early spring, there is what the company calls "its first line of gender-specific adult absorbent underwear."
That would be Depend protective underwear for men and women. There's a pink waistband for women and a blue one for men. Moreover, the leg opening for men is narrower than it is for women.
"One of the key insights we got was.......read the whole story
For more dementia information, click here
For Alzheimer's and dementia activities, click here
For information on being the best caregiver you can be, click here
For a great resource for those with dementia, caregivers and healthcare professinals, click here
Subscribe to:
Posts (Atom)

